Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)

Click to increase image sizeClick to decrease image size

Declaration of interest

G Leclercq, M Bacac, and C Klein declare patent applications with Roche. All authors are employees of Roche. All the authors declare ownership of Roche stock. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.